Andrew D Redfern
Overview
Explore the profile of Andrew D Redfern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoon S, Lau P, White A, Bulsara M, Banks P, Redfern A
Cochrane Database Syst Rev
. 2021 May;
5:CD011220.
PMID: 34037241
Background: Retrospective analyses suggest that capecitabine may carry superior activity in hormone receptor-positive relative to hormone receptor-negative metastatic breast cancer. This review examined the veracity of that finding and explored...
12.
Hofman M, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J, et al.
Lancet
. 2021 Feb;
397(10276):797-804.
PMID: 33581798
Background: Lutetium-177 [Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castration-resistant prostate cancer....
13.
Eckhardt B, Cao Y, Redfern A, Chi L, Burrows A, Roslan S, et al.
Cancer Res
. 2020 Jan;
80(6):1304-1315.
PMID: 31941699
Metastasis is the major cause of death in patients with cancer; with no therapeutic cure, treatments remain largely palliative. As such, new targets and therapeutic strategies are urgently required. Here,...
14.
Sorolla A, Wang E, Golden E, Duffy C, Henriques S, Redfern A, et al.
Oncogene
. 2019 Oct;
39(6):1167-1184.
PMID: 31636382
In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed...
15.
Kretzmann J, Evans C, Moses C, Sorolla A, Kretzmann A, Wang E, et al.
Chem Sci
. 2019 Oct;
10(33):7718-7727.
PMID: 31588320
Aberrant gene expression is a hallmark of cancer. Although transcription is traditionally considered 'undruggable', the development of CRISPR-associated protein 9 (Cas9) systems offers enormous potential to rectify cancer-associated transcriptional abnormalities...
16.
Sorolla A, Wang E, Clemons T, Evans C, Plani-Lam J, Golden E, et al.
Nanomedicine
. 2019 May;
20:102003.
PMID: 31055077
Triple negative breast cancers (TNBC) are aggressive malignancies for which chemotherapy is the only treatment option. Many TNBC acquire chemotherapy resistance, notably docetaxel, which has been associated with the overexpression...
17.
Hart N, Galvao D, Saunders C, Taaffe D, Feeney K, Spry N, et al.
Trials
. 2018 Dec;
19(1):695.
PMID: 30572928
Background: Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with...
18.
Yeo B, Redfern A, Mouchemore K, Hamilton J, Anderson R
Clin Exp Metastasis
. 2018 Jul;
35(4):255-267.
PMID: 29968171
Granulocyte-colony stimulating factor (G-CSF) is one of several cytokines that can expand and mobilize haematopoietic precursor cells from bone marrow. In particular, G-CSF mobilizes neutrophils when the host is challenged...
19.
Redfern A, Spalding L, Thompson E
Clin Exp Metastasis
. 2018 Jun;
35(4):285-308.
PMID: 29948647
Epithelial mesenchymal transition (EMT) describes the shift of cells from an epithelial form to a contact independent, migratory, mesenchymal form. In cancer the change is linked to invasion and metastasis....
20.
Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, et al.
JAMA Oncol
. 2018 Jan;
4(3):302-308.
PMID: 29327055
Importance: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did...